文献速递临床试验与 GCP

托吡酯对超重/肥胖精神分裂症患者减重的有效性:一项随机对照试验的研究方案

Topiramate's effectiveness on weight reduction in overweight/obese persons with schizophrenia: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2017-09-20

本研究为在斯里兰卡门诊开展的双盲随机对照试验方案,计划纳入90例精神分裂症患者,比较托吡酯联合抗精神病药与安慰剂联合抗精神病药(照常治疗)对体重等人体测量指标的影响,主要结局为基线至3个月期间每月记录的人体测量指标变化,次要结局为简明精神病评定量表症状变化。

要点

  • 托吡酯作为抗精神病药附加治疗,目标剂量为每日100 mg,对照为安慰剂。
  • 主要结局为体重、腰围、皮褶厚度和体质指数在3个月内的变化。
  • 次要结局为临床医生用简明精神病评定量表评估的症状变化。

核心结论

  • 该研究方案旨在评估托吡酯作为附加治疗与照常治疗相比对精神分裂症患者体重控制的有效性。
  • 作者认为这是南亚地区首个此类研究,该地区代谢风险高于西方且可能存在与精神分裂症体重增加相关的独特种族因素。

研究设计与样本

  • 双盲随机对照试验方案,在斯里兰卡科伦坡北教学医院门诊开展。
  • 计划纳入90例精神分裂症患者,采用置换区组随机化等分为干预组和对照组。
  • 干预组在抗精神病药基础上按预设给药方案使用托吡酯,目标剂量为每日100 mg;对照组接受安慰剂。
  • 排除合并代谢性疾病及正在服用处方减重药物的患者。
  • 研究周期为3个月,基线及每月记录人体测量指标,并在基线及研究期间评估简明精神病评定量表。

主要发现

  • 原文为研究方案,未报告研究结果。

关键数值与推荐

  • 主要结局为体重、腰围、皮褶厚度和体质指数在基线和3个月研究期间每月记录的变化。
  • 次要结局为临床医生用简明精神病评定量表评估的症状变化。
  • 干预组托吡酯目标剂量为每日100 mg。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Schizophrenia is a psychiatric disorder with a higher mortality than that of the general population. Most of the deaths are due to cardiovascular causes and are related to metabolic risks. This risk is due not only to antipsychotics but also to inherent factors of the disorder. Studies in the West have shown topiramate to be effective in schizophrenia to reduce weight gain and for symptomatic control. Whether this is effective for South Asians is not known. It is important because South Asians have a higher risk of metabolic syndrome. We aim to conduct a double-blind, randomized controlled trial comparing topiramate add-on therapy with treatment as usual with antipsychotics in patients with schizophrenia in an outpatient setting in Sri Lanka. METHODS/DESIGN: Ninety patients with schizophrenia presenting to the Colombo North Teaching Hospital will be randomized to intervention and control groups equally using permuted block randomization. Patients with comorbid metabolic disorders and taking prescribed weight-controlling medications will be excluded. The intervention group will be prescribed topiramate in addition to their antipsychotics in a predefined dosing regimen targeting a dose of 100 mg per day. The control subjects are to receive a placebo. As the primary outcome, anthropometric measurements including weight, waist circumference, skinfold thickness, and body mass index will be recorded at baseline and monthly during the study period of 3 months. The secondary outcome is the change in symptoms according to the clinician-administered Brief Psychiatric Rating Scale. Assessment of capacity will be performed and informed consent obtained from all subjects. Ethics approval has been obtained from the ethical review committee of the Faculty of Medicine, University of Kelaniya, and the trial has been registered in the Sri Lanka Clinical Trials Registry. DISCUSSION: In this double-blind, randomized controlled trial, we will attempt to assess the effectiveness of topiramate as an add-on therapy compared with treatment as usual for weight control in patients with schizophrenia. To our knowledge, this is the first such study in South Asia, where metabolic risks are found to be higher than in the West and could have unique ethnic factors related to weight gain in schizophrenia. TRIAL REGISTRATION: Sri Lanka Clinical Trials Registry, SLCTR/2017/003 . Registered on 20 February 2017. Universal trial number, U1111-1192-9439.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Chandradasa M, Champika L, de Silva S, et al. Topiramate's effectiveness on weight reduction in overweight/obese persons with schizophrenia: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28931411. doi:10.1186/s13063-017-2162-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。